News

Published on 14 Feb 2025 on Investing.com

Neurocrine Biosciences' chief corporate affairs officer sells shares worth...


Article preview image

David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX),...

NASDAQ.NBIX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
High Growth Tech Stocks To Watch In February 2025

Over the last 7 days, the United States market has dropped 2.2%, yet it remains up by 18% over th...

Simply Wall St. · via Yahoo Finance 24 Feb 2025

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we ...

Insider Monkey · via Yahoo Finance 21 Feb 2025

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its...

Even though Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) posted strong earnings, investors appeare...

Simply Wall St. · via Yahoo Finance 21 Feb 2025

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, ...

Insider Monkey · via Yahoo Finance 18 Feb 2025

Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts By...

Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts

Investing.com 18 Feb 2025

Neurocrine Biosciences chief commercial officer sells $251,426 in stock By...

Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently...

Investing.com 14 Feb 2025

Neurocrine Biosciences' chief corporate affairs officer sells shares worth...

David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX),...

Investing.com 14 Feb 2025

Neurocrine Biosciences CEO sells shares for $298,907 By Investing.com

SAN DIEGO—Gano Kyle, the Chief Executive Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a...

Investing.com 14 Feb 2025

Neurocrine Biosciences director Sherwin sells $1.6m in stock By Investing.com

SAN DIEGO—Stephen A. Sherwin, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.4...

Investing.com 14 Feb 2025

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking a...

Zacks · via Yahoo Finance 3 Feb 2025